Enriching Tumor-Reactive CD8+ T Cells via PD-1 and TIM-3 Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for obtaining tumor-reactive T cells from peripheral blood are inefficient, as T cells isolated from peripheral blood may not exhibit sufficient tumor-specific reactivity, hindering the effectiveness of adoptive cell therapy for cancer treatment.
Innovation Solution
Selecting CD8+ T cells that express PD-1 and/or TIM-3 biomarkers from peripheral blood mononuclear cells to enrich for tumor-reactive T cells, allowing for their separation and potential use in therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If T cells are isolated from peripheral blood using conventional methods, then the procedure is simple and quick, but the tumor-specific reactivity is insufficient
Solution Approach 1:
The patent changes the selection parameters from conventional markers (CD3, CD8) to include exhaustion markers PD-1 and TIM-3. By selecting T cells that co-express CD8 with PD-1 and/or TIM-3, the method identifies tumor-reactive cells more reliably. This parameter change resolves the contradiction by improving tumor-specific reactivity while maintaining a manageable selection process using standard flow cytometry techniques.
2Reliability
If screening for autologous tumor recognition is performed to ensure tumor reactivity, then tumor-specific reactivity is improved, but the time of in vitro culture increases
Solution Approach 1:
The patent performs preliminary selection of tumor-reactive T cells using PD-1 and TIM-3 markers before in vitro culture. By pre-enriching the desired cell population based on surface marker expression, the method eliminates the need for lengthy screening assays during culture expansion. This preliminary action resolves the contradiction by ensuring tumor reactivity is established before culture begins, significantly reducing in vitro culture time while maintaining high tumor-specific reactivity.
3Quantity of substance
If CD8+ T cells expressing PD-1 and TIM-3 are specifically selected, then the enrichment of tumor-reactive T cells is improved, but the device complexity and procedural steps increase
Solution Approach 1:
The patent uses surface markers PD-1 and TIM-3 as intermediary indicators to identify tumor-reactive T cells. These markers serve as proxies that correlate with tumor reactivity without requiring direct functional assays. By using these intermediary markers, the method achieves high enrichment of tumor-reactive cells through standard flow cytometry, resolving the contradiction by maintaining procedural simplicity while dramatically improving cell enrichment quality.
Data Source
AI summary
Methods of obtaining a cell population enriched for tumor-reactive T cells, the method comprising: (a) obtaining a bulk population of peripheral blood mononuclear cells (PBMCs) from a sample of peripheral blood; (b) specifically selecting CD8+ T cells that also express PD-1 and/or TIM-3 from the bulk population; and (c) separating the cells selected in (b) from unselected cells to obtain a cell population enriched for tumor-reactive T cells are disclosed. Related methods of administering a cell population enriched for tumor-reactive T cells to a mammal, methods of obtaining a pharmaceutical composition comprising a cell population enriched for tumor-reactive T cells, and isolated or purified cell populations are also disclosed.